BOSTON--(BUSINESS WIRE)--Sep. 27, 2018--
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused
on developing and commercializing medicines to improve the survival and
quality of life of cancer patients, today announced that the Company
will present at the following upcoming investor conferences:
The Cantor Fitzgerald Global Healthcare Conference on Tuesday, October
2, 2018 at 4:00pm EDT in New York City, NY, USA
The Leerink Partners Roundtable Series: Rare Disease & Oncology on
Wednesday, October 3, 2018 at 8:00am EDT in New York City, NY, USA
A live webcast of each presentation will be available on the investors
section of the Company’s website at www.verastem.com.
An archived presentation will be available for 90 days.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical
company committed to the development and commercialization of medicines
to improve the lives of patients diagnosed with cancer. We are driven by
the strength, tenacity and courage of those battling cancer –
single-minded in our resolve to deliver new therapies that not only keep
cancer at bay, but improve the lives of patients diagnosed with cancer.
Because for us, it’s personal.
Our first FDA approved product is now available for the treatment of
patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).
Our pipeline comprises product candidates that seek to treat cancer by
modulating the local tumor microenvironment. For more information,
please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180927005885/en/
Source: Verastem, Inc.
Brian Sullivan, +1 781-469-1636
Director, Corporate Development
Silverstein, +1 917-697-9313
Joseph Rayne, +1 617-340-6075